The latest price target for Coherus BioSciences (NASDAQ:CHRS) was reported by Baird on December 5, 2024. The analyst firm set a price target for $6.00 expecting CHRS to rise to within 12 months (a possible 300.24% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for Coherus BioSciences (NASDAQ:CHRS) was provided by Baird, and Coherus BioSciences maintained their outperform rating.

The last upgrade for Coherus BioSciences Inc happened on March 28, 2023 when UBS raised their price target to $11. UBS previously had a neutral for Coherus BioSciences Inc.

The last downgrade for Coherus BioSciences Inc happened on August 16, 2024 when UBS changed their price target from $4 to $1.5 for Coherus BioSciences Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Coherus BioSciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Coherus BioSciences was filed on December 5, 2024 so you should expect the next rating to be made available sometime around December 5, 2025.

While ratings are subjective and will change, the latest Coherus BioSciences (CHRS) rating was a maintained with a price target of $4.00 to $6.00. The current price Coherus BioSciences (CHRS) is trading at is $1.50, which is out of the analyst’s predicted range.